Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1

Conditions

Hemophilia A 2Lymphoma, Follicular 1

Interventions

Cyclophosphamide 31fludarabine phosphate 28Mycophenolic Acid 21Cyclosporine 21Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 17Antilymphocyte Serum 17Cord Blood Stem Cell Transplantation 15Busulfan 15Tacrolimus 13Radiotherapy 11Filgrastim 11Methotrexate 9Methylprednisolone 8Melphalan 8fludarabine 6Etoposide 5Epoetin Alfa 5Cytarabine 4Thiotepa 3Therapeutics 3Darbepoetin alfa 3thymoglobulin 2merphos 2Vorinostat 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2Flow Cytometry 2Cyclosporins 2Bortezomib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Factor VIII × Classical hematology × Clear all
NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡